US biopharmaceutical company Halozyme Therapeutics Inc (NASDAQ: HALO) said on Tuesday that it will release its financial and operating results for the third quarter of 2025 on Monday, 3 November 2025, following the close of trading.

Halozyme will host a conference call on 3 November at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137280.

A live webcast and replay of the conference call will also be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.

Halozyme's ENHANZE drug delivery technology is used to facilitate the subcutaneous delivery of injected drugs and fluids. The company also develops, manufactures and commercialises drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.